我国学者在光动力疗法用于宫颈癌防控领域取得新进展

Core Viewpoint - The clinical study published in the journal "Med" demonstrates the effectiveness and safety of a new photodynamic therapy, APL-1702, for treating high-grade squamous intraepithelial lesions (HSIL) of the cervix, marking a significant advancement in cervical cancer prevention [1][2] Group 1: Study Overview - The study is a rigorous multi-center, randomized, double-blind trial conducted globally, confirming the efficacy and safety of APL-1702 [1] - A total of 402 patients with confirmed high-grade squamous intraepithelial lesions (CIN2 and CIN3) were enrolled in the trial, which was conducted across 61 international centers [2] Group 2: Treatment Methodology - APL-1702 utilizes a novel approach where a photosensitizer is absorbed by HPV-infected cells, followed by LED light exposure to induce cell death, overcoming limitations of previous intravenous photosensitizers [2] - The treatment involves a 2:1 random allocation to either the APL-1702 treatment group or a placebo control group, using a local application of 5% aminolevulinic acid and specific wavelength light [2] Group 3: Clinical Implications - The non-invasive nature of this therapy better preserves cervical structure and physiological function, providing a safer option for women that effectively controls lesions while maximizing future pregnancy safety [2]